SCHEMBL198658

SCHEMBL198658

CCCCOC(=O)C(=O)OC(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.50
ATM Q13315 1/20 0.47
TSHR P16473 5/20 0.46
HPGD P15428 1/20 0.44
HCAR2 Q8TDS4 1/20 0.41
NAAA Q02083 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
RAD52 P43351 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
EPHX1 P07099 1/20 0.38
ESR1 P03372 2/20 0.38
LMNA P02545 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C19 P33261 1/20 0.38
NR1H2 P55055 1/20 0.38
RNASEL Q05823 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10777181 0.92 TSHR (0.56) ALDH1A1TSHRHCAR2NAAARAD52
SCHEMBL21202163 0.92 TSHR (0.56) ALDH1A1TSHRHCAR2NAAARAD52
SCHEMBL2992405 0.87 HCAR2 (0.38) ALDH1A1TSHRHCAR2TDP1ESR1
SCHEMBL5501929 0.84 ALDH1A1 (0.67) ALDH1A1ATMTSHRHPGDHCAR2
SCHEMBL28787473 0.84 ALDH1A1 (0.67) ALDH1A1ATMTSHRHPGDHCAR2
SCHEMBL137155 0.84 ALDH1A1 (0.67) ALDH1A1ATMTSHRHPGDHCAR2
SCHEMBL9305347 0.83 TSHR (0.66) ALDH1A1ATMTSHRHPGDHCAR2
SCHEMBL28131973 0.82 ALDH1A1 (0.64) ALDH1A1ATMTSHRHPGDHCAR2
Fluoride SCHEMBL3958324 0.82 ALDH1A1 (0.64) ALDH1A1ATMTSHRHPGDHCAR2
SCHEMBL5501926 0.82 ALDH1A1 (0.64) ALDH1A1ATMTSHRHPGDHCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120016126-A1 METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE DONG-A PHARMACEUTICAL. CO., LTD (KR) 2012-01-19 US claimed
EP-1989220-B1 HIV FUSION INHIBITOR PEPTIDES WITH IMPROVED BIOLOGICAL PROPERTIES TRIMERIS INC (US) 2011-12-14 EP claimed
EP-0538692-A1 Use of partly known substituted pyrrolidine derivatives as pharmaceuticals, new compounds and process for their preparation BAYER AG (DE) 1993-04-28 EP claimed
EP-3259255-A1 (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID Theravance Biopharma R&D IP, LLC (US) 2017-12-27 EP disclosed
EP-3256446-A1 (2S, 4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID AS NEPRILYSIN INHIBITOR Theravance Biopharma R&D IP, LLC (US) 2017-12-20 EP disclosed
EP-1373185-B1 HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE AMINEX THERAPEUTICS INC (US) 2017-03-01 EP disclosed
WO-2016133803-A1 (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID THERAVANCE BIOPHARMA R&D IP, LLC (US) 2016-08-25 WO disclosed
WO-2016130650-A1 (2S, 4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID AS NEPRILYSIN INHIBITOR THERAVANCE BIOPHARMA R&D IP, LLC (US) 2016-08-18 WO disclosed
US-9066954-B2 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2015-06-30 US disclosed
US-8865935-B2 Purification methods for betulonic acid and Boc-lysinated betulonic acid, and organic synthesis of betulonic acid amides with piperazine derivatives KOREA INSTITUTE OF ENERGY RESEARCH (KR) 2014-10-21 US disclosed
US-20140243527-A1 PURIFICATION METHODS FOR BETULONIC ACID AND BOC-LYSINATED BETULONIC ACID, AND ORGANIC SYNTHESIS OF BETULONIC ACID AMIDES WITH PIPERAZINE DERIVATIVES KOREA INSTITUTE OF ENERGY RESEARCH (KR) 2014-08-28 US disclosed
US-5885979-A SQUALENE SYNTHETASE INHIBITOR TREATING OR PREVENTING HYPERLIPIDEMIA TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-03-23 US disclosed
US-5843693-A Assay method for screening for inhibitors of proTNF conversion CHIRON CORPORATION (US) 1998-12-01 US disclosed
US-5726306-A INHIBITORS OF SQUALENE SYNTHETASE AND FUNGAL GROWTH; USEFUL IN TREATING AND PREVENTING HYPERLIPIDEMIA TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-03-10 US disclosed
WO-1997002286-A1 NOVEL ANTIBIOTIC PEPTIDES MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE (KR) 1997-01-23 WO disclosed
EP-0567026-A1 4,1-Benzoxazepin derivatives as squalene synthase inhibitors and their use in the treatment of hypercholesteremia and as fungicides TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-10-27 EP disclosed
EP-0464430-A1 2-Aminoalkyl-pyrrolealdehyde, process of preparation and use CASSELLA Aktiengesellschaft (DE) 1992-01-08 EP disclosed
US-4735651-A HERBICIDES; ROOT INHIBITION THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1988-04-05 US disclosed
WO-1988000950-A2 PRODUCTION OF COVALENT-LINKED CONJUGATES FROM AN ANTIBIOTIC AND A NON-TOXIC DERIVATIVE OF POLYMYXINE B FAUCHERE JEAN LUC (CH) 1988-02-11 WO disclosed
EP-0192135-A2 Oligopeptidylargininol derivatives and their homologues, process for their preparation, their use and agents containing them BEHRINGWERKE Aktiengesellschaft (DE) 1986-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016126-A1 METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE DPP4, DPP3, DPP7 ALDH1A1 752/4885ATM 4671/4885TSHR 2902/4885
US-20140243527-A1 PURIFICATION METHODS FOR BETULONIC ACID AND BOC-LYSINATED BETULONIC ACID, AND ORGANIC SYNTHESIS OF BETULONIC ACID AMIDES WITH PIPERAZINE DERIVATIVES BET1, LOX, BECN1 ALDH1A1 3355/4885ATM 4028/4885TSHR 3657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.